Where We Stand: AMCP believes that payors must have the flexibility to use mail service delivery of prescription drugs as a component of their prescription drug benefit.
Press Release: Focusing on what’s best for the patient, leveraging technology to perform real-time benefit checks, and developing trust and transparency among stakeholders are some of the suggestions to emerge from AMCP’s recent Partnership Forum on “Optimizing Prior Authorization for Appropriate Medication Selection.”
A retrospective cohort study published in JMCP found that MTM programs targeting a resolution of medication-related problems resulted in reductions in health care utilization and increased medication adherence.
Extended-release opioid agonists and antagonists represent an alternative treatment strategy for opioid use disorder. However their value is low for the money, according to this summary of an ICER analysis published in JMCP.
The benefits of extended release opioid agonists and antagonists in the highly personalized space of opioid use disorder treatment are described in this JMCP article by the CMO of Drug & Alcohol Treatment Centers, Pathway Healthcare.
The benefits of extended release opioid agonists and antagonists in the highly personalized space of opioid use disorder treatment are described in this JMCP article by the CMO of Drug & Alcohol Treatment Centers, Pathway Healthcare.
Extended-release opioid agonists and antagonists represent an alternative treatment strategy for opioid use disorder. However their value is low for the money, according to this summary of an ICER analysis published in JMCP.